Indian regulators have turned their attention to pay-for-delay agreements, making the nation the latest to scrutinize such agreements that have particular impact on the pharmaceutical industry.
According to reports, the Competition Commission of India is examining patent settlements made between foreign brand-name pharmaceutical companies and their generic counterparts in India. Reports say the probe is in response to concerns that some of those settlements may lead to cheaper, generic drugs being unavailable to consumers.
Reports say at least two patent settlements are being investigated by the CCI. One of which involves Roche’s lung cancer drug and an agreement the pharma giant made with generic drug maker Cipla. The other, reports say, involves Glenmark Pharmaceuticals, one of India’s largest generic companies, and an agreement with Merck over a diabetes drug.
Officials noted that the agreements will be probed on a case-by-case basis to determine if they resulted in anticompetitive effects.
Full content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
US Senators Present AI Strategy, Call for Funding Surge
May 15, 2024 by
CPI
Hausfeld Strengthens Competition Bench with Key Hires in London and Germany
May 15, 2024 by
CPI
UK’s CMA Investigates Education Software Company for Market Abuse
May 14, 2024 by
CPI
Schumer Urges FTC Caution on Chevron’s $53B Hess Deal Over Gas Price Fears
May 14, 2024 by
CPI
Amazon Urges US Judge to Block FTC Probe into Data Preservation
May 14, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI